Evidence map›Paper›PMID 31647614›Full record

Trial reportESC heart failure2019

Impaired glucose tolerance and albuminuria in patients with chronic heart failure: a subanalysis of the SUPPORT trial.

Kotaro Nochioka, Yasuhiko Sakata, Masanobu Miura, Takashi Shiroto, Jun Takahashi, Chie Saga, Yasuko Ikeno, Nobuyuki Shiba, Tsuyoshi Shinozaki, Masafumi Sugi and 11 more

Open access · goldAbstract readRandomized Controlled Trial
In one paragraph

Trial report in ESC heart failure, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Review
  6. Article
  7. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 12 institutions in 1 country.

Kotaro NochiokaDepartment of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Seiryo-machi 1-1, Sendai, Miyagi, 980-8574, Japan.
Yasuhiko SakataDepartment of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Seiryo-machi 1-1, Sendai, Miyagi, 980-8574, Japan.
Masanobu MiuraDepartment of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Seiryo-machi 1-1, Sendai, Miyagi, 980-8574, Japan.
Takashi ShirotoDepartment of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Seiryo-machi 1-1, Sendai, Miyagi, 980-8574, Japan.
Jun TakahashiDepartment of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Seiryo-machi 1-1, Sendai, Miyagi, 980-8574, Japan.
Chie SagaDepartment of Evidence-based Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Miyagi, Japan.
Yasuko IkenoDepartment of Evidence-based Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Miyagi, Japan.
Nobuyuki ShibaDepartment of Cardiovascular Medicine, International University of Health and Welfare Hospital, Tochigi, Japan.
Tsuyoshi ShinozakiCardiovascular Division, Sendai Medical Center, National Hospital Organization, Miyagi, Japan.
Masafumi SugiCardiovascular Division, Iwaki City Medical Center, Fukushima, Japan.
Makoto NakagawaDepartment of Cardiovascular Medicine, Iwate Prefectural Isawa Hospital, Iwate, Japan.
Tatsuya KomaruDepartment of Cardiovascular Medicine, Tohoku Medical and Pharmaceutical University, Miyagi, Japan.
Atsushi KatoDepartment of Cardiovascular Medicine, Sendai Open Hospital, Miyagi, Japan.
Eiji NozakiDepartment of Cardiovascular Medicine, Iwate Prefectural Central Hospital, Iwate, Japan.
Kaoru IwabuchiCardiovascular Division, Osaki Citizen Hospital, Miyagi, Japan.
Tetsuya HiramotoCardiovascular Division, Kurihara Central Hospital, Miyagi, Japan.
Kanichi InoueCardiovascular Division, Senen Rifu Hospital, Miyagi, Japan.
Masatoshi OheCardiovascular Division, Kojirakawa Shieido Hospital, Miyagi, Japan.
Kenji TamakiCardiology Department, Iwate Health Service Association, Iwate, Japan.
Ichiro TsujiDivision of Epidemiology, Department of Public Health and Forensic Medicine, Tohoku University Graduate School of Medicine, Miyagi, Japan.
Hiroaki ShimokawaDepartment of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Seiryo-machi 1-1, Sendai, Miyagi, 980-8574, Japan.
Tohoku University · JPIwate Prefectural Central Hospital · JPFukushima Medical University · JPInternational University of Health and Welfare · JPIwate Medical University · JPKoga Hospital · JPKurashiki Central Hospital · JPOsaki Citizen Hospital · JPSendai Medical Center · JPSendai Shakai Hoken Hospital · JPSenshio Rifu hospital · JPTohoku Medical and Pharmaceutical University Hospital · JP

Funding

Ministry of Education, Culture, Sports, Science and TechnologyMinistry of Health, Labour and Welfare, Japan
6 · The paper itself

Abstract

aimsThe study aims to evaluate the prognostic significance of impaired glucose tolerance (IGT) with reference to albuminuria in patients with chronic heart failure (CHF). METHODS AND

resultsWe examined 535 CHF patients (mean 66 years, women 25%) in the control arm of our SUPPORT trial, in which we examined additive impact of olmesartan in hypertensive patients with symptomatic CHF treated with β-blockers and/or angiotensin-converting enzyme inhibitors. We examined the association between glycaemic abnormality (assessed by 75 g of oral glucose tolerance test) and albuminuria for a composite outcome of all-cause death, myocardial infarction, stroke, and HF hospitalization. IGT patients (N = 113, mean 67.2 years) were older and more frequently treated with β-blockers compared with those with normal glucose regulation (N = 142, mean 64.0 years) and those with diabetes mellitus (N = 280, mean 65.7 years). Multivariable Cox proportional hazard models revealed that, as compared with normal glucose regulation (NGR), IGT was associated with increased risk of the outcome when complicated by albuminuria [hazard ratio (HR) 2.25; 95% confidence interval (CI) 1.14-4.42; P = 0.019] but not when uncomplicated by albuminuria (HR 0.76; 95% CI 0.35-1.60, P = 0.47) (P for interaction = 0.041). This was also the case for diabetes mellitus and albuminuria (HR 2.06; 95% CI 1.17-3.61; P = 0.012). Among IGT patients without albuminuria, 21 (29%) developed albuminuria at 1-year visit, which was again associated with poor prognosis (HR 7.36; 95% CI 1.39-38.98, P = 0.019).

conclusionsThese results indicate that IGT is associated with poor prognosis when complicated by albuminuria in CHF patients, demonstrating the importance of combined early stages of glucose intolerance and renal dysfunction in the management of CHF.

Indexed as

AlbuminuriaGlucose IntoleranceHeart FailureAgedBlood GlucoseChronic DiseaseDiabetes Mellitus, Type 2FemaleHumansMaleMiddle AgedPrognosisBlood GlucoseAlbuminuriaChronic heart failureDiabetes mellitusImpaired glucose tolerance

Identifiers

PMID31647614
PMCPMC6989294
OpenAlexW2981884990

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.